PE20050333A1 - Derivados de 4-indolilsufonamidas como moduladores del receptor de serotonina (5-ht6) - Google Patents
Derivados de 4-indolilsufonamidas como moduladores del receptor de serotonina (5-ht6)Info
- Publication number
- PE20050333A1 PE20050333A1 PE2004000737A PE2004000737A PE20050333A1 PE 20050333 A1 PE20050333 A1 PE 20050333A1 PE 2004000737 A PE2004000737 A PE 2004000737A PE 2004000737 A PE2004000737 A PE 2004000737A PE 20050333 A1 PE20050333 A1 PE 20050333A1
- Authority
- PE
- Peru
- Prior art keywords
- aliphatic radical
- indol
- dimethylaminoethyl
- indolylsufonamides
- derivatives
- Prior art date
Links
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 title abstract 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 title abstract 2
- 150000003254 radicals Chemical class 0.000 abstract 5
- -1 2-DIMETHYLAMINOETHYL Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 4-INDOLILSUFONAMIDAS DE FORMULA IA, EN LA CUAL R1 ES NR8R9 O UN RADICAL CICLOALIFATICO; R2, R3, R5, R6 Y R7 SON, INDEPENDIENTEMENTE ENTRE SI, H, HALOGENO, NITRO, ALCOXI, CIANO, ENTRE OTROS; R4 ES H O UN RADICAL ALIFATICO; A ES UN SISTEMA DE ANILLO AROMATICO MONO O POLICICLICO; N ES 0, 1, 2, 3 O 4; R8 Y R9 SON, INDEPENDIENTEMENTE ENTRE SI, H O UN RADICAL ALIFATICO, ENTRE OTROS, CON LA CONDICION DE QUE R8 Y R9 NO REPRESENTAN AL MISMO TIEMPO H, Y SI UNO DE ELLOS, R8 O R9, REPRESENTA UN RADICAL ALIFATICO C1-C4, EL OTRO DE ELLOS REPRESENTA UN RADICAL ALIFATICO CON AL MENOS 5 ATOMOS DE CARBONO. SON COMPUESTOS PREFERIDOS: N-[1-(2-DIMETILAMINOETIL)-1H-INDOL-4-IL]-5-CLORO-3-METILBENZO[B]TIOFENO-2-SULFONAMIDA; N-[1-(2-DIMETILAMINOETIL)-1H-INDOL-4-IL]-NAFTALENO-2-SULFONAMIDA; N-[1-(2-DIMETILAMINOETIL)-1H-INDOL-4-IL]-NAFTALENO-1-SULFONAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION DE ESTOS DERIVADOS Y UN MEDICAMENTO QUE LOS CONTIENE. ESTOS COMPUESTOS REGULAN EL RECEPTOR DE SEROTONINA (5-HT6) Y SON UTILES PARA EL TRATAMIENTO DE LOS DESORDENES RELACIONADOS CON ESTE RECEPTOR COMO OBESIDAD, ENFERMEDADES CORONARIAS, DIABETES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200301807A ES2222829B1 (es) | 2003-07-30 | 2003-07-30 | Derivados de 4-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050333A1 true PE20050333A1 (es) | 2005-06-12 |
Family
ID=34130541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004000737A PE20050333A1 (es) | 2003-07-30 | 2004-08-02 | Derivados de 4-indolilsufonamidas como moduladores del receptor de serotonina (5-ht6) |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8097643B2 (es) |
| EP (1) | EP1648446B1 (es) |
| JP (1) | JP2007500166A (es) |
| KR (1) | KR20060123698A (es) |
| CN (1) | CN100518736C (es) |
| AT (1) | ATE432700T1 (es) |
| AU (1) | AU2004262486A1 (es) |
| BR (1) | BRPI0413068A (es) |
| CA (1) | CA2534098A1 (es) |
| DE (1) | DE602004021385D1 (es) |
| EC (2) | ECSP066322A (es) |
| ES (2) | ES2222829B1 (es) |
| IL (1) | IL172892A0 (es) |
| MX (1) | MXPA06001137A (es) |
| NO (1) | NO20060155L (es) |
| NZ (1) | NZ545300A (es) |
| PE (1) | PE20050333A1 (es) |
| PT (1) | PT1648446E (es) |
| RU (1) | RU2006105778A (es) |
| TW (1) | TW200505855A (es) |
| WO (1) | WO2005013978A1 (es) |
| ZA (1) | ZA200600421B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200870385A1 (ru) * | 2006-03-29 | 2009-04-28 | Фолдркс Фармасьютикалз, Инк. | Ингибирование токсичности альфа-синуклеина |
| DE102007007751A1 (de) * | 2007-02-16 | 2008-08-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007012284A1 (de) * | 2007-03-16 | 2008-09-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP2018861A1 (en) * | 2007-07-26 | 2009-01-28 | Laboratorios del Dr. Esteve S.A. | 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain |
| DE102007035333A1 (de) * | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102007035334A1 (de) * | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP2020230B1 (en) | 2007-08-01 | 2011-01-19 | Laboratorios del Dr. Esteve S.A. | Combination of at least two 5-HT6-Ligands |
| DE102007042154A1 (de) | 2007-09-05 | 2009-03-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
| EP2053052A1 (en) | 2007-10-23 | 2009-04-29 | Laboratorios del Dr. Esteve S.A. | Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide |
| AU2009256009B2 (en) * | 2008-06-06 | 2014-02-06 | Neurmedix, Inc. | Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds |
| US20190336585A1 (en) * | 2018-05-03 | 2019-11-07 | John Lawrence Mee | Method for sustainable human cognitive enhancement |
| US20190390193A1 (en) * | 2018-06-23 | 2019-12-26 | John Lawrence Mee | Reversible method for sustainable human cognitive enhancement |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3472870A (en) * | 1966-08-29 | 1969-10-14 | Mead Johnson & Co | Sulfonamidotryptamines |
| GB9317764D0 (en) * | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
| NZ305166A (en) | 1995-03-20 | 1998-12-23 | Lilly Co Eli | 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments |
| US5939451A (en) * | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
| GB9902459D0 (en) * | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| US6043706A (en) | 1999-02-05 | 2000-03-28 | Ericsson Inc. | Methods and apparatus for controlling power amplifier quiescent current in a wireless communication device |
| US6521658B1 (en) * | 1999-05-28 | 2003-02-18 | Abbott Laboratories | Cell proliferation inhibitors |
| GB9926302D0 (en) | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
| CN1275967C (zh) | 2001-01-30 | 2006-09-20 | 伊莱利利公司 | 用作5－ht6受体拮抗剂的苯磺酸吲哚－5－基酯 |
| ES2187300B1 (es) | 2001-11-14 | 2004-06-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. |
| DE602004016491D1 (de) | 2003-05-09 | 2008-10-23 | Esteve Labor Dr | Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen |
-
2003
- 2003-07-30 ES ES200301807A patent/ES2222829B1/es not_active Expired - Fee Related
-
2004
- 2004-07-29 MX MXPA06001137A patent/MXPA06001137A/es unknown
- 2004-07-29 AU AU2004262486A patent/AU2004262486A1/en not_active Abandoned
- 2004-07-29 ES ES04763611T patent/ES2327848T3/es not_active Expired - Lifetime
- 2004-07-29 US US10/566,164 patent/US8097643B2/en not_active Expired - Fee Related
- 2004-07-29 KR KR1020067001467A patent/KR20060123698A/ko not_active Withdrawn
- 2004-07-29 EP EP04763611A patent/EP1648446B1/en not_active Expired - Lifetime
- 2004-07-29 WO PCT/EP2004/008512 patent/WO2005013978A1/en not_active Ceased
- 2004-07-29 CA CA002534098A patent/CA2534098A1/en not_active Abandoned
- 2004-07-29 ZA ZA200600421A patent/ZA200600421B/en unknown
- 2004-07-29 NZ NZ545300A patent/NZ545300A/en unknown
- 2004-07-29 BR BRPI0413068-5A patent/BRPI0413068A/pt not_active Application Discontinuation
- 2004-07-29 RU RU2006105778/04A patent/RU2006105778A/ru unknown
- 2004-07-29 DE DE602004021385T patent/DE602004021385D1/de not_active Expired - Lifetime
- 2004-07-29 AT AT04763611T patent/ATE432700T1/de not_active IP Right Cessation
- 2004-07-29 JP JP2006521530A patent/JP2007500166A/ja active Pending
- 2004-07-29 PT PT04763611T patent/PT1648446E/pt unknown
- 2004-07-29 CN CNB2004800221691A patent/CN100518736C/zh not_active Expired - Fee Related
- 2004-07-29 TW TW093122672A patent/TW200505855A/zh unknown
- 2004-08-02 PE PE2004000737A patent/PE20050333A1/es not_active Application Discontinuation
-
2005
- 2005-12-29 IL IL172892A patent/IL172892A0/en unknown
-
2006
- 2006-01-10 NO NO20060155A patent/NO20060155L/no not_active Application Discontinuation
- 2006-01-26 EC EC2006006322A patent/ECSP066322A/es unknown
- 2006-01-26 EC EC2006006324A patent/ECSP066324A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20070185158A1 (en) | 2007-08-09 |
| CN1829508A (zh) | 2006-09-06 |
| TW200505855A (en) | 2005-02-16 |
| JP2007500166A (ja) | 2007-01-11 |
| NZ545300A (en) | 2008-05-30 |
| CA2534098A1 (en) | 2005-02-17 |
| WO2005013978A1 (en) | 2005-02-17 |
| NO20060155L (no) | 2006-01-10 |
| DE602004021385D1 (de) | 2009-07-16 |
| ES2222829A1 (es) | 2005-02-01 |
| AU2004262486A1 (en) | 2005-02-17 |
| ES2327848T3 (es) | 2009-11-04 |
| ES2222829B1 (es) | 2006-03-01 |
| BRPI0413068A (pt) | 2006-10-17 |
| ZA200600421B (en) | 2007-03-28 |
| EP1648446A1 (en) | 2006-04-26 |
| ECSP066322A (es) | 2006-08-30 |
| MXPA06001137A (es) | 2006-04-24 |
| PT1648446E (pt) | 2009-09-03 |
| ATE432700T1 (de) | 2009-06-15 |
| RU2006105778A (ru) | 2007-09-20 |
| CN100518736C (zh) | 2009-07-29 |
| IL172892A0 (en) | 2006-06-11 |
| KR20060123698A (ko) | 2006-12-04 |
| US8097643B2 (en) | 2012-01-17 |
| ECSP066324A (es) | 2006-08-30 |
| EP1648446B1 (en) | 2009-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037222A1 (es) | Un derivado de indol, su uso, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, y un procedimiento para preparar dicha composicion | |
| PE20050333A1 (es) | Derivados de 4-indolilsufonamidas como moduladores del receptor de serotonina (5-ht6) | |
| EA200600048A1 (ru) | Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором | |
| PA8493801A1 (es) | Moduladores del receptor glucocorticoide | |
| UY28578A1 (es) | Derivados de amida | |
| ES2163071T3 (es) | Sulfonamidas y su utilizacion. | |
| AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
| UY25180A1 (es) | Derivados de carboxamidotiazoles, su preparación, composiciones farmacéuticas que los contienen. | |
| PA8493701A1 (es) | Compuestos para tratar la obesidad | |
| PE20050726A1 (es) | Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos | |
| DK0593513T3 (da) | Tryptaminanaloger, deres syntese og deres anvendelse som 5-HT,-lignende eller 5-HT2-receptoragonister | |
| CR10062A (es) | Composiciones y metodos de tratamiento para trastornos del sistema nervioso central | |
| NO20050014L (no) | 1-Heterosyklylalkyl-3-sulfonylindol eller -indazolderivater som 5-hydroksytryptamin-6 ligander | |
| BRPI0415657A (pt) | derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c | |
| CY1113559T1 (el) | Παραγωγα υποκατεστημενης αζεπινης ως ρυθμιστες υποδοχεων σεροτονινης | |
| ES2193875B2 (es) | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. | |
| AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
| EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
| PA8575001A1 (es) | Fluorobenzamidas como inhibidores de maob | |
| UY27232A1 (es) | Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos | |
| PE20040763A1 (es) | Derivados de aminoalcoxiindoles como ligandos de los receptores 5-ht6 | |
| PH12022500015A1 (en) | Ccr6 receptor modulators | |
| AR028475A1 (es) | Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion. | |
| AR049405A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo | |
| CO4410330A1 (es) | Nuevos derivados de bencimidazol farmacologicamente activos y sus sales de adicion acida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |